An evaluation of ticagrelor for the treatment of sickle cell anemia.
Jaime Ribeiro-FilhoSètondji Cocou Modeste Alexandre YahouédéhouThassila Nogueira PitangaSânzio Silva SantanaElisângela Vitória AdornoCynara Gomes BarbosaJúnia Raquel Dutra FerreiraEugênia Terra Granado PinaJoelma Santana Dos Santos NeresIvana Paula Ribeiro LeiteIsa Menezes LyraMarilda de Souza GonçalvesPublished in: Expert review of hematology (2020)
While phase 1 and 2 clinical trials demonstrated satisfactory tolerability and safety, the conclusion of phase 3 clinical trials is crucial to prove the efficacy of ticagrelor as a therapeutic option for the treatment of SCD. Thus, it is expected that ticagrelor, especially in combination with other drugs, will improve the clinical profile and quality of life of patients with SCD.